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Background: Many patients with enlarged vestibular aqueduct (EVA) have either only one allelic mutant of the
SLC26A4 gene or lack any detectable mutation. In this study, multiplex ligation-dependent probe amplification
(MLPA) was used to screen for copy number variations (CNVs) of SLC26A4 and to reveal the pathogenic mechanisms
of non-syndromic EVA (NSEVA).
Methods: Between January 2003 and March 2010, 923 Chinese patients (481 males, 442 females) with NSEVA were
recruited. Among these, 68 patients (7.4%) were found to carry only one mutant allele of SLC26A4 and 39 patients
(4.2%) lacked any detectable mutation in SLC26A4; these 107 patients without double mutant alleles were assigned
to the patient group. Possible copy number variations in SLC26A4 were detected by SALSA MLPA.
Results: Using GeneMapper, no significant difference was observed between the groups, as compared with the
standard probe provided in the assay. The results of the capillary electrophoresis showed no significant difference
between the patients and controls.
Conclusion: Our results suggest that CNVs and the exon deletion in SLC26A4 are not important factors in NSEVA.
However, it would be premature to conclude that CNVs have no role in EVA. Genome-wide studies to explore CNVs
within non-coding regions of the SLC26A4 gene and neighboring regions are warranted, to elucidate their roles in
NSEVA etiology.
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Copy number variations (CNVs) or copy number poly-
morphisms are complex gains or losses of several to hun-
dreds of kilobases of DNA as a result of deletions,
insertions, duplications, and complex multi-site variants.
CNVs are found throughout the human genome [1].
CNVs are much more frequent than chromosomal aberra-
tions. They also encompass more nucleotide content per
genome than single-nucleotide polymorphisms (SNPs)
[2,3]. Therefore, CNVs may be more significantly corre-
lated with phenotypic variations, and they may play vital
roles in the evolution and development of species [4].* Correspondence: hdy301@263.net; daipu301@vip.sina.com
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reproduction in any medium, provided the orMultiplex ligation-dependent probe amplification (MLPA)
was used to screen for CNVs of the SLC26A4 gene in
the present study. MLPA is a novel semi-quantitative
method that was first developed by Schouten and collea-
gues in 2002 [5]. It allows the simultaneous processing
of multiple sequences (up to 45) with various copy num-
bers. MLPA involves the hybridization of probes and
target sequences, followed by ligation and PCR amplifica-
tion. The amplified products are visualized by capillary
electrophoresis, and the peak area and peak height of the
amplified products are analyzed to reveal the relative
copy number of the target sequence.
SLC26A4, which is also known as the Pendred syn-
drome (PDS) gene, is located on human chromosome
7q31. It contains 57175 bp and its mRNA is 4930 bp in
length, encompassing 21 exons and containing an open
reading frame (ORF) of 2343 bp. The ORF starts fromd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SLC26A4 encodes Pendrin, which has a molecular mass
of 86 kDa and contains 780 amino acids [6]. Pendrin is
a transmembrane protein that is mainly composed of
hydrophobic amino acids. It is a member of the
anion transporter family and contains an intracellular
N-terminus, a C-terminus, and 12 transmembrane
domains. Pendrin is expressed in the cells of the thyroid
gland, kidney, and inner ear. Pendrin functions in the




2–, OH–, Cl–, I–, and C6H12O6 . Therefore, it plays
a crucial role in maintaining the balance of ions [7].
In the inner ear, Pendrin is primarily expressed in the
non-sensory structures, such as the external sulcus epi-
thelial cells of the Corti organ and the endolymphatic
duct and sac epithelial cells, and is involved in endo-
lymphic fluid homeostasis. Pendrin, as a transporter of
Cl–/HCO3
–, regulates the ion balance of the endolymphic
fluid [8]. Mutations in the SLC26A4 gene may lead to
autosomal-recessive deafness (DFNB4) and Pendred syn-
drome (non-syndromic enlarged vestibular aqueduct
[NSEVA], inner ear malformation, sensorineural hearing
loss, and goiter) [9].
SLC26A4 gene mutations have the characteristic of
allelic heterogeneity, i.e., deaf patients from different
races may have a spectrum of mutations. In Northern
Europe, T416P and IVS8 + 1 G>A are considered to be
the most common mutations [10], while in France, the
mutations are extremely diverse [11]. Among Asians,
H723R is the most frequently observed mutation in
Japanese and Korean populations [12,13], while 919-2A
>G is the most common mutation in Chinese subjects
[14,15]. One study has indicated that SLC26A4 biallelic
mutations (homozygote or complex heterozygote) cause
NSEVA, while a person with a monoallelic mutation can
only be a carrier [16]. However, many EVA patients have
only one or no mutant allele of the SLC26A4 gene. One
explanation for the pathogenesis of these EVA cases is
that the mutation is located within the promoter region
or intronic cryptic splicing; these types of mutations are
not readily detected by current screening approaches
[17]. Another study has suggested the involvement of
environmental factors or mutations in other genes [18].
However, these speculations have not been confirmed
by relevant studies.
In the current study, we recruited patients with
NSEVA who had no detectable SLC26A4 mutation or
only carried one mutant allele of SLC26A4. All the
cases were diagnosed by the Molecular Diagnostics
Center for Deafness, Institute of Otorhinolaryngology,
PLA General Hospital. To date, no study of CNVs in
SLC26A4 has been conducted. In the present study, we
used MLPA to screen patients for SLC26A4 CNVs and
to reveal the pathogenic mechanisms of NSEVA.Materials and Methods
Recruitment of subjects
Patients with NSEVA
Between January 2003 and March 2010, 923 patients
(481 males, 442 females) who were diagnosed as hav-
ing NSEVA by computer tomography (CT) or MRI were
recruited at the Molecular Diagnostics Center for
Deafness, Institute of Otorhinolaryngology, PLA General
Hospital. Among these patients, 262 (28.4%) carried
SLC26A4 homozygous mutations and 554 (60%) had
complex heterozygous mutations. For the current study,
68 patients (7.4%) with one allele mutant and 39 patients
(4.2%) without any detectable mutation were recruited.
The average age of the 68 patients (32 males and
36 females) who carried one allele mutation in SLC26A4
was 7.86 years (range, 3 months to 33 years; SD= 7.56).
The average age of the 39 patients (23 males and
16 females) who lacked SLC26A4 mutation was 9.65 years
(range, 1–34 years; SD= 8.95). All the NSEVA cases were
diagnosed by high-resolution CT or MRI. Vestibular
aqueduct enlargement was diagnosed if the vestibular
aqueduct was >1.5 mm in the middle portion of the
descending limb in the axial plane, based on a CT scan
of the temporal bone [19]. The MRI diagnostic criteria
for vestibular enlargement included: diameter of the
intra-osseous endolymphatic duct at its midpoint being
>1.5 mm, an enlarged intra-osseous endolymphatic sac;
and the T2-weighted signal intensity of the endolym-
phatic duct being designated as “high” [20].
“Healthy” controls
Controls were recruited from persons with a normal
hearing examination and no family history of hereditary
hearing loss. Genomic DNA samples were collected from
these subjects as negative (wild-type) controls. In accord-
ance with the MLPA experimental design criterion that
the ratio of patients to controls should be 7:1, 16 con-
trols (8 males and 8 females) were selected for the
current study. The average age of the control subjects
was 9.23 years (range, 2–36 years; SD= 8.76). No statisti-
cally significant difference in age was observed between
the patients and controls.
All patients and controls signed informed consent forms,
and this study obtained the approval of the People’s Liber-
ation Army General Hospital Ethics Committee.
DNA extraction, quantification, and quality assessment
DNA samples were extracted from the peripheral blood
leukocytes using standard procedures. The extracted
DNA was stored at −20°C until use. The DNA concen-
tration and absorbance were measured in a spectropho-
tometer (Beckman Coulter DU800) at 280 nm and
260 nm. The ratio of absorbance readings at 260 nm and
280 nm (A260/A280) provides an estimate of the purity
Figure 1 Image of the bilateral enlarged vestibular aqueducts.





NSEVA cases 107 8.73 (8.27) 1.1:1
Controls 16 9.23 (8.76) 1:1
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A260/A280 ratios of between 1.5 and 2.0.
MLPA analysis
CNVs in the SLC26A4 gene were detected using the
SALSA MLPA KIT P280-A1 Pendred-SLC26A4 kit
(MRC Holland, Amsterdam, The Netherlands). MLPA
permits relative quantification of changes in the copy
number of a specific genomic region. The P280 Pendred-
SLC26A4 probe mix contains probes for each of the 21
exons of the SLC26A4 gene. In addition, two mutation-
specific probes were designed for the IVS8+ 1 G>A
donor splice mutation and the T416P amino acid substi-
tution. MLPA was performed in accordance with the
manufacturer’s instructions (MRC Holland). Briefly, DNA
samples were diluted with TE to 5 μl and heated at 98°C
for 5 min. After cooling the samples to 25°C, 1.5 μl of
probe mix (containing 1 fmol of each probe) and 1.5 μl of
MLPA hybridization buffer were added, and the solution
was denatured at 95°C for 1 min and hybridized at 60°C
for 16 h. Hybridized probes were ligated at 54°C for
15 min after the addition of 32 μl of the ligation mixture.
Following heat inactivation at 98°C for 5 min, 10 μl of
the ligation reaction were mixed with 30 μl of PCR
buffer, heated to 60°C, mixed with 10 μl of PCR mix-
ture and amplified by PCR (35 cycles of 30 s at 95°C,
30 s at 60°C, and 1 min at 72°C, followed 1 cycle of
20 min at 72°C). The following PCR primers were
used: forward, 5′-GGGTTCCCTAAGGGTTGGA-3′;
and reverse, 5′-GTGCCAGCAAGATCCAATCTAGA-3′.
The amplified products were analyzed in the ABI 3130
Avant capillary electrophoresis system. The genes and
sequences recognized by the probes used in the present
study can be found at www.mrc-holland.com.
Results
Characteristics of the study subjects
The NSEVA group included 107 patients who either
carry one allele mutation in the SLC26A4 gene or lack a
detectable mutation in SLC26A4. All cases were diag-
nosed and confirmed as NSEVA by CT and MRI scan
(Figure 1). In total, 16 “healthy” controls were selected
from subjects with a normal hearing examination and no
family history of hereditary hearing loss. No significant
differences were found for age or gender between the
patients and controls (p< 0.05) (Table 1).
Comparisons of the experimental data for the patients
and controls
Experimental data were generated using the Gene-
Mapper Software (ver. 3.7), and included six aspects:
dye/sample peak; sample file name; size; height; area;
and data-points. The preliminary data analyses did not
reveal significant differences for capillary electrophoresisprofile or for sample peak, size, height, area, and data-
points. Some of the results are shown in Figure 2.
All the data were analyzed further using the Coffalyser
MLPA Software, which generates a relative ratio from
a comparison of the patients and controls. This ratio
is regarded as ‘normal’ when it is within the range of
0.5–1.5. A ratio of <0.5 suggests a fragment deletion, while
a ratio >1.5 indicates duplication. All the results for the
107 patients showed a normal ratio, which suggests that
these patients lacked CNVs (deletions or duplications).Discussion
The difference in genome sequences between individuals is
generally estimated to be less than 0.1%, and the differences
are mainly manifested as SNPs. However, with the comple-
tion of the Human Genome Project, it is becoming clear
that the genomic differences among healthy individuals are
>0.1%, and include many variations [21]. The individual
genomic variations may be quantitatively described as copy
number gains (insertions and duplications), losses (dele-
tions), transpositions (translocations and rearrangements),
and inversions. Compared with SNPs, the frequency of
CNVs is low, although the implicated sequences are much
longer than SNPs, indicating that CNVs may have a greater
impact on human diseases and health [22]. To date, more
than 6,000 CNVs (http://projects.tcag.ca/variation) have
been identified in the human genome. There have been
reports of significant correlations between CNVs and deaf-
ness. For example, Knijnenburg et al. found a homozygous
deletion on 15q15.3 in a CNV using comparative genomic
hybridization (CGH) and MLPA [23]. This deletion of
approximately 90 kb contains four genes, including the
STRC gene linked to the DFNB16 locus. The latter is
Figure 2 GeneMapper analysis. No significant difference was observed compared to the standard probe provided in the assay. The chart shows
the results of capillary electrophoresis for one patient (upper panel) and one control subject (upper panel). There is no significant difference
between the samples.
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Another study has reported that complex rearrangements
of the 7q21.3 region are related to bilateral split-foot mal-
formation and hearing loss [24]. MLPA, which is a semi-
quantitative method with good sensitivity based on a sim-
ple quantitative PCR reaction, allows the simultaneous
hybridization and ligation of probes. When this is followedby PCR amplification and capillary electrophoresis analysis,
MLPA can detect multiple CNVs within DNA sequences
[25,26]. This method has been widely used to study inher-
ited diseases. In the current study, we applied MLPA to
screen for CNVs in a deafness-related gene, SLC26A4.
The SLC26A4 gene was first localized and cloned by
Everett and colleagues from patients with Pendred
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and an ORF of 2343 bp. A clear demarcation was found
between each intron and exon. The multiple exons
observed in the gene indicate that it encodes a protein
with a complex structure and function. The ORF of
SLC26A4 starts at exon 2 and continuously traverses the
other 20 exons. The exons are 55 bp to 231 bp in length
and encode the Pendrin protein, which contains 780
amino acids [6]. Pendrin is composed of hydrophobic
amino acids and belongs to the anion transporter fam-
ilies. Its functions are associated with the transportation
of anions, such as I–, Cl–, and HCO3
– [28].
Pendrin is primarily expressed in the external sulcus
epithelial cells of the Corti organ and the endolymphatic
duct and sac in the inner ear. These non-sensory struc-
tures are correlated with the metabolism of endolymphic
fluid. Pendrin, as a transporter of Cl–, may regulate the
ion balance of the endolymphic fluid. It is well known
that the homeostasis of the endolymphic fluid plays
a pivotal role in the development of the inner ear.
If homeostasis is disrupted, the osseous structures of
the cochlea and vestibular aqueduct may be affected.
Therefore, mutations in SLC26A4 may lead to enlarge-
ment of the vestibular aqueduct [29].
Mutations in the SLC26A4 gene are considered to be
extremely heterogeneous [30]. The distributions of mu-
tant SLC26A4 alleles differ significantly among various
ethnic populations [14,31,32]. Many different types of
variations in SLC26A4 have been found, including mis-
sense, nonsense, splice site, and frameshift mutations.
However, there has been no report as to whether CNVs
exist in the SLC26A4 gene, which is the main topic of
the current study.
We applied MLPA to screen for CNVs in the 21 exons
of the SLC26A4 gene in 107 patients with NSEVA who
carry one or no mutant allele of SLC26A4. However, the
results did not reveal any copy number gain or loss in
the SLC26A4 genes of these patients. There were several
possible explanations for this observation. First, it is pos-
sible that no CNVs are present in the exons of SLC26A4,
which would mean that CNVs are not the cause of the
enlarged vestibular aqueduct. Second, CNVs may be
present in SLC26A4 but are located within the introns or
lie upstream or downstream of the regulatory regions, i.
e., not within the ORF. The MLPA assay is unable to de-
tect these CNVs. Third, CNVs may exist in the genes
adjacent to SLC26A4 or in genes with regulatory func-
tions for SLC26A4. These CNVs may alter the expression
patterns or the functions of target genes, thereby indir-
ectly affecting the SLC26A4 gene, and ultimately causing
enlargement of the vestibular aqueduct. Based on these
results and interpretations, it is premature to conclude
that CNV has no causative role in enlarged vestibular
aqueduct. Genome-wide studies to explore CNVs withinthe non-coding regions of SLC26A4 are warranted, to
elucidate their roles in the etiology of NSEVA.
Conclusion
Our results suggest that CNVs and the exon deletion in
SLC26A4 are not important factors in NSEVA. However,
it would be premature to conclude that CNVs have no
role in EVA. Genome-wide studies to explore CNVs
within non-coding regions of the SLC26A4 gene and
neighboring regions are warranted in order to elucidate
their roles in NSEVA etiology.
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